AbbVie vs Amgen
AbbVie is the larger business, with $61.16bn of revenue in fiscal 2025 against $36.75bn for Amgen (1.7 times as much). Amgen grew faster (10.0% against 8.6%). Amgen kept more of each dollar of sales as profit: a net margin of 21.0% against 6.9%.
| Latest fiscal year | AbbVieABBV, 2025 | AmgenAMGN, 2025 |
|---|---|---|
| Revenue | $61.16bn | $36.75bn |
| Revenue growth | 8.6% | 10.0% |
| Net income | $4.23bn | $7.71bn |
| Operating margin | 24.6% | 24.7% |
| Net margin | 6.9% | 21.0% |
| Return on equity | — | 106.1% |
| Free cash flow | $17.82bn | $8.10bn |
| Cash | $5.23bn | $9.13bn |
| Total debt | $67.50bn | $54.60bn |
| Debt to equity | — | 630.7% |
| Dividend per share | $6.65 | $9.66 |
| Dividend yield | 2.4% | 2.1% |
| Share buybacks | $980m | $0 |
| Employees | 57,000 | — |
| Market value | $505.48bn | $249.43bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 87 (Strong) | 89 (Strong) |
| Insider trades, 12 months | 0 buys, 6 sales | 0 buys, 14 sales |